SLC6A3 and schizophrenia: Thus, it is possible that differences in levels of DAT between patients with schizophrenia and controls could be greater in BA 10 from medication naïve individuals, a notion supported by an increase in the significance in the difference between desmethylimipramine-insensitive mazindol-sensitive [3H]mazindol binding in BA 10 from subjects with schizophrenia if FRADD or LEAP was included as a covariate.